# US 2021/0330768 A1 · Methods of treating fungal infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330768 A1
- Document ID: US20210330768A1
- Status: Published application
- Kind: A1
- Application number: 17/224,888
- Filed: 2021-04-07
- Published: 2021-10-28
- Earliest claimed: 2016-07-11
- Assignees: Rutgers, The State University of New Jersey
- Applicants: Rutgers, The State University of New Jersey
- Inventors: Chaoyang Xue; Amariliz Rivera
- Web page: https://patentgrep.com/patent/US20210330768A1

## CPC

- A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/10: Antimycotics
- A61K 2039/521: {inactivated (killed)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention describes vaccine compositions and their methods of use utilizing inactivated fbp1Δ deletion mutant fungal cells.

## Claims

### Claim 1

A method of treating a fungal infection in a subject in need thereof comprising administering to the subject a vaccine comprising an inactivated F-box protein 1 deletion (fbp1Δ) mutant Cryptococcus neoformans cell, wherein the inactivated fbpΔ mutant cell is heat-killed, and wherein the (fbp1Δ) is a full deletion or a partial deletion.

### Claim 2 (depends on 1)

The method of claim 1, further comprising administering at least one adjuvant to the subject.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering at least one antifungal agent to the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the administering step is repeated more than once.

### Claim 5 (depends on 1)

The method of claim 1, wherein the fungal infection comprises an infection with a virulent strain of C. neoformans.

### Claim 6 (depends on 1)

The method of claim 1, wherein the fungal infection comprises an infection with C. albicans, A. fumigatus, or C. gattii.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is an immunocompromised subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the immunocomprised subject is infected with human immunodeficiency virus (HIV).

### Claim 9 (depends on 1)

The method of claim 1, wherein the (fbp1Δ) is a full deletion.

### Claim 10 (depends on 1)

The method of claim 1, wherein the fbpΔ is a partial deletion.

### Claim 11 (depends on 10)

The method of claim 10, wherein the partial deletion is of an F-box domain.

### Claim 12 (depends on 1)

The method of claim 1, wherein the vaccine further comprises at least one adjuvant.

### Claim 13 (depends on 1)

The method of claim 1, wherein the vaccine further comprises a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

The method of claim 1, wherein the fbpΔ occurs by homologous recombination.

### Claim 15 (depends on 1)

The method of claim 1, wherein the partial deletion occurs by homologous recombination.
